Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 276

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial

Open access
van den Boogaard, Mark, Slooter, Arjen J. C., Brüggemann, Roger J. M., Schoonhoven, Lisette, Beishuizen, Albertus, Vermeijden, J. Wytze, Pretorius, Danie, de Koning, Jan, Simons, Koen S., Dennesen, Paul J. W., Van der Voort, Peter H. J., Houterman, Saskia, van der Hoeven, J. G., Pickkers, Peter, and the REDUCE Study Investigators, van der Woude, Margaretha C. E., Besselink, Anna, Hofstra, Lieuwe S., Spronk, Peter E., van den Bergh, Walter, Donker, Dirk W., Fuchs, Malaika, Karakus, Attila, Koeman, M., van Duijnhoven, Mirella, Hannink, Gerjon · 2018 · JAMA

Abstract

Importance: Results of studies on use of prophylactic haloperidol in critically ill adults are inconclusive, especially in patients at high risk of delirium. Objective: To determine whether prophylactic use of haloperidol improves survival among critically ill adults at high risk of delirium, which was defined as an anticipated intensive care unit (ICU) stay of at least 2 days. Design, Setting, and Participants: Randomized, double-blind, placebo-controlled investigator-driven study involving 1789 critically ill adults treated at 21 ICUs, at which nonpharmacological interventions for delirium prevention are routinely used in the Netherlands. Patients without delirium whose expected ICU stay was at least a day were included. Recruitment was from July 2013 to December 2016 and follow-up was conducted at 90 days with the final follow-up on March 1, 2017. Interventions: Patients received prophylactic treatment 3 times daily intravenously either 1 mg (n = 350) or 2 mg (n = 732) of haloperidol or placebo (n = 707), consisting of 0.9% sodium chloride. Main Outcome and Measures: The primary outcome was the number of days that patients survived in 28 days. There were 15 secondary outcomes, including delirium incidence, 28-day delirium-free and coma-free days, duration of mechanical ventilation, and ICU and hospital length of stay. Results: All 1789 randomized patients (mean, age 66.6 years [SD, 12.6]; 1099 men [61.4%]) completed the study. The 1-mg haloperidol group was prematurely stopped because of futility. There was no difference in the median days patients survived in 28 days, 28 days in the 2-mg haloperidol group vs 28 days in the placebo group, for a difference of 0 days (95% CI, 0-0; P = .93) and a hazard ratio of 1.003 (95% CI, 0.78-1.30, P=.82). All of the 15 secondary outcomes were not statistically different. These included delirium incidence (mean difference, 1.5%, 95% CI, -3.6% to 6.7%), delirium-free and coma-free days (mean difference, 0 days, 95% CI, 0-0 days), and duration of mechanical ventilation, ICU, and hospital length of stay (mean difference, 0 days, 95% CI, 0-0 days for all 3 measures). The number of reported adverse effects did not differ between groups (2 [0.3%] for the 2-mg haloperidol group vs 1 [0.1%] for the placebo group). Conclusions and Relevance: Among critically ill adults at high risk of delirium, the use of prophylactic haloperidol compared with placebo did not improve survival at 28 days. These findings do not support the use of prophylactic haloperidol for reducing mortality in critically ill adults. Trial Registration: clinicaltrials.gov Identifier: NCT01785290.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2018.0160

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 276

Metadata

Authors
van den Boogaard, M., Slooter, A. J. C., Brüggemann, R. J. M., Schoonhoven, L., Beishuizen, A., Vermeijden, J. W., Pretorius, D., de Koning, J., Simons, K. S., Dennesen, P. J. W., Van der Voort, P. H. J., Houterman, S., van der Hoeven, J. G., Pickkers, P., and the REDUCE Study Investigators, van der Woude, M. C. E., Besselink, A., Hofstra, L. S., Spronk, P. E., van den Bergh, W., Donker, D. W., Fuchs, M., Karakus, A., Koeman, M., van Duijnhoven, M., & Hannink, G.
Venue
JAMA
Published
2018-02-20
Volume
319
Issue
7
Pages
680
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2793524874
Cited by
276
References
33
FWCI
32.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2018.0160
The paper
van den Boogaard, M., Slooter, A. J. C., Brüggemann, R. J. M., Schoonhoven, L., Beishuizen, A., Vermeijden, J. W., Pretorius, D., de Koning, J., Simons, K. S., Dennesen, P. J. W., Van der Voort, P. H. J., Houterman, S., van der Hoeven, J. G., Pickkers, P., and the REDUCE Study Investigators, van der Woude, M. C. E., Besselink, A., Hofstra, L. S., Spronk, P. E., . . . Hannink, G. (2018). Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2018.0160

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.